• Something wrong with this record ?

Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study

M. Magner, K. Thorová, V. Župová, M. Houška, I. Švandová, P. Novotná, J. Tříska, N. Vrchotová, I. Soural, L. Jílek

. 2023 ; 15 (3) : . [pub] 20230131

Language English Country Switzerland

Document type Randomized Controlled Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004483

Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3-7 years that were treated with sulforaphane.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004483
003      
CZ-PrNML
005      
20230425141433.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/nu15030718 $2 doi
035    __
$a (PubMed)36771424
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Magner, Martin $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital, 128 08 Prague 2, Czech Republic $1 https://orcid.org/0000000258839509
245    10
$a Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study / $c M. Magner, K. Thorová, V. Župová, M. Houška, I. Švandová, P. Novotná, J. Tříska, N. Vrchotová, I. Soural, L. Jílek
520    9_
$a Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3-7 years that were treated with sulforaphane.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    12
$a autistická porucha $x farmakoterapie $7 D001321
650    12
$a poruchy autistického spektra $x farmakoterapie $7 D000067877
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a prospektivní studie $7 D011446
650    _2
$a isothiokyanatany $x terapeutické užití $7 D017879
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Thorová, Kateřina $u National Institute for Autism, 180 00 Prague 8, Czech Republic
700    1_
$a Župová, Veronika $u National Institute for Autism, 180 00 Prague 8, Czech Republic
700    1_
$a Houška, Milan $u Food Research Institute Prague, 102 00 Prague 10, Czech Republic $1 https://orcid.org/0000000151350412
700    1_
$a Švandová, Ivana $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital, 128 08 Prague 2, Czech Republic
700    1_
$a Novotná, Pavla $u Food Research Institute Prague, 102 00 Prague 10, Czech Republic
700    1_
$a Tříska, Jan $u Global Change Research Institute CAS, 603 00 Brno, Czech Republic $1 https://orcid.org/0000000338462158
700    1_
$a Vrchotová, Naděžda $u Global Change Research Institute CAS, 603 00 Brno, Czech Republic
700    1_
$a Soural, Ivo $u Faculty of Horticulture, Mendel University in Brno, 691 44 Lednice, Czech Republic
700    1_
$a Jílek, Ladislav $u Pure Food Norway, 1400 Ski, Norway
773    0_
$w MED00189563 $t Nutrients $x 2072-6643 $g Roč. 15, č. 3 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36771424 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141430 $b ABA008
999    __
$a ok $b bmc $g 1924904 $s 1190692
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 3 $e 20230131 $i 2072-6643 $m Nutrients $n Nutrients $x MED00189563
LZP    __
$a Pubmed-20230418
Back

Find record

Citation metrics

Archiving options